SOPHiA GENETICS announced a multi-year collaboration with AstraZeneca to develop and commercialize two companion diagnostics supporting precision oncology therapies. The partnership will focus on creating decentralized diagnostics for solid tumors and blood cancers, enabling local labs worldwide to perform standardized tests from day one of drug approval. This effort aims to improve patient access to targeted treatments by combining AI-driven biomarker detection with rapid deployment through SOPHiA GENETICS's global data platform. The collaboration supports advancing precision medicine by connecting healthcare institutions globally to enhance clinical decision-making and patient outcomes.
AstraZeneca announced that its drug Tezspire met all primary and key secondary goals in a late-stage trial for eosinophilic esophagitis, a chronic condition causing inflammation and difficulty swallowing. The trial involved 368 patients who received ...
AstraZeneca has priced a €2.55 billion bond issuance split into four fixed-rate tranches maturing between 2030 and 2038. The bonds, issued by its US subsidiary and guaranteed by the parent company, carry coupons ranging from 3.402% to 4.169%, reflect...
AstraZeneca faced a setback with the discontinuation of its volrustomig trial for non-small cell lung cancer, but strong clinical results for drugs like Tagrisso and Enhertu support its growth prospects. Investment firm CICC gave AstraZeneca an "Outp...
